Porsche Cars North America today officially opened its new $100 million Porsche Experience Center (PEC) and headquarters in Atlanta, Georgia. The 27-acre complex located at the Northeast corner of Hartsfield-Jackson Atlanta International Airport is the largest investment outside Germany for the sports car manufacturer. The industry-first facility is complete with a driver development track, classic car gallery, restoration center, human performance center and driving simulator lab. A state-of-the-art business center features 13,000 square feet of conference and event space and a fine dining restaurant. The experience center has been specifically designed as a destination for the public, including automotive enthusiasts and Porsche customers.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7477151-100-million-porsche-experience-center/
When Amway™ asked for help in raising awareness about global childhood malnutrition through its Nutrilite™ Power of 5 Campaign, more than 260,000 people across the globe raised their hand to do just that. And they broke a GUINNESS WORLD RECORDS™ title in the process.
As a global leader in nutrition research, development and innovation, Amway paired its expertise from Nutrilite™, the world’s number one selling vitamins and dietary supplements brand*, with its passion for helping people live better lives. Amway™ last year launched the Nutrilite™ Power of 5 Campaign to expand the distribution of the Nutrilite™ Little Bits™ supplement. At the time, the micronutrient powder with 15 essential vitamins and minerals for children was being distributed in two countries through established programs run by Non-Governmental Organizations. It has since expanded to nine countries and there are plans for more.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7214653-amway-guinness-world-record/
Men and women are biologically different – and so are their skincare needs. This premise fueled the development of the Artistry® brand’s latest scientifically advanced skincare collection, Artistry® Men.
Artistry® scientists’ findings and expertise led to this customized collection, which targets men’s two primary skincare needs – oil control and hydration – to reveal healthier-, younger-looking skin in men of all ages and ethnicities.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72394510-amway-artistry-skincare-for-men/
In response to the devastation wrought by Saturday’s earthquake and powerful aftershocks in Nepal, the Ad Council has joined the U.S. Agency for International Development’s Center for International Disaster Information (USAID CIDI) to launch a series of television, print and digital public service advertisements (PSAs) encouraging Americans to make financial contributions to disaster relief efforts. The PSAs direct audiences to visit CIDI.org/NepalRelief, where they can contribute to support the short and long-term recovery operations, providing supplies and services to those affected by the earthquake.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7512851-ad-council-nepal-earthquake-relief/
Easter Seals, one of the country’s leading providers of child development services, introduces a new video with a cast of animated characters to help parents understand the importance of monitoring their child’s development. Make the First Five Count (makethefirstfivecount.org) is a movement to ensure all children are entering kindergarten with the right skills to succeed alongside their peers.
“Easter Seals is dedicated to ensuring all children have every opportunity to reach their full potential,” said Katy Beh Neas, Easter Seals’ Executive Vice President of Government Relations. “We’ve created this new video to help parents learn the basics of child development. At the new website, parents can find a screening tool and other information designed to support the well-being of children. Monitoring development should be treated as a common part of our annual routines, like spring cleaning or a trip to the dentist.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7172751-easter-seals-make-the-first-five-count/
Everyday Health, Inc. (NYSE: EVDY), today announced the launch of the What to Expect Pregnancy Clock Apple Watch™ app. Everyday Health, Inc. is a leading digital health and wellness company that operates the digital assets of What to Expect, Heidi Murkoff’s world-renowned pregnancy and parenting brand.
Designed specifically for the Apple Watch, the What to Expect Pregnancy Clock delivers a pregnancy countdown (to the second) – with weekly updates and visual growth milestones to track progress, actionable tips and notifications synchronized to the baby’s growth and development, and other relevant pregnancy information on demand. All of this gives expectant parents-to-be convenient, personalized, and discreet access to essential information about their baby’s development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7221451-pregnancy-clock-apple-watch-app/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Neighbors across the country will soon have an exciting opportunity to help change their communities for the better through State Farm Neighborhood Assist®. This philanthropic program awards 40 causes a $25,000 grant. Anyone in the United States can submit a cause beginning March 9 through March 30. Ultimately, voters will decide which community improvement projects win big.
Returning for its fourth year, State Farm Neighborhood Assist asks individuals to identify causes that would help make their communities safer, stronger and better-educated. Up to 4,000 causes will be accepted. The State Farm Youth Advisory Board (YAB) will then narrow down the field, using a scoring rubric to identify the top 200 submissions. The public will have a chance to vote 10 times a day from May 14 through June 3 for their favorite causes from the list of finalists. The 40 causes that receive the most votes will win a $25,000 grant. The nominations and votes will be accepted exclusively through a free Facebook app.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7417331-state-farm-neighborhood-assist/
Volvo Cars presents a unique, complete system solution that makes it possible to integrate self-driving cars into real traffic – with ordinary people in the driver’s seat.
“We are entering uncharted territory in the field of autonomous driving,” says Dr Peter Mertens, Senior Vice President Research and Development of Volvo Car Group. “Taking the exciting step to a public pilot, with the ambition to enable ordinary people to sit behind the wheel in normal traffic on public roads, has never been done before.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7443851-volvo-first-self-driving-car-system/
Triax Technologies Inc and Washington Youth Soccer have announced a long-term partnership to track and assess head impacts among top level youth players. Findings from the large scale collection of data will be used to identify trends and potential risks to inform training protocols which will be publically shared to encourage best practices.
Players from the Washington Youth Soccer Elite Player Development (EPD) program (U12-U18) will wear the Triax Technologies Smart Impact Monitors (SIM™) as they compete in the prestigious US Youth Soccer Region IV Olympic Development Program (ODP) Championships January 8–11 in Phoenix, AZ, and will continue throughout their careers with Washington Youth Soccer.
Triax SIM™ devices are worn in comfortable, unobtrusive headbands to record head impacts, and transmit data in real time from the field to a smart phone or tablet on the sideline. This cutting edge technology allows players to track up to 180 individual head impacts measuring the G–force of direct hits and jarring through linear and rotational measures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7416151-triax-technologies-impact-monitoring/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
